1. EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Treatment Options For EGFR Mutation-Positive NSCLC

4. The Relationship Between EGFR Mutations and CNS Involvement

5. Challenges With EGFR Mutation-Positive NSCLC With CNS Involvement

6. Challenges With Brain Metastases

7. Cognitive Effects of WBRT

8. Challenges With Leptomeningeal Disease

9. Retrospective Analysis of Erlotinib and Gefitinib Activity in the CNS

10. Gefitinib

11. Erlotinib

12. Pulse Dosing With Erlotinib

13. Afatinib

14. Subgroup Analysis From LUX-Lung 3 and LUX-Lung 6 Trials

15. Osimertinib

16. CNS Data From AURA 3

17. Leptomeningeal Disease Data From BLOOM

18. CNS Data From FLAURA

19. Emerging Agents

20. Where to Start: TKI or Radiotherapy?

21. What Is the Role of Stereotactic Radiosurgery?

22. The Evolution of Practice

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)